🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. BPS804

    Mereo BioPharma Group plc

    Chronic-kidney Disease Stage 5D on Stable Hemodialysis

    phase 2 small molecule terminated

    1 trial

  2. BRENSOCATIB, MOMETASONE , BRENSOCATIB, The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP.

    Insmed Limited

    Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

    phase 2 small molecule active

    1 trial

  3. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  4. BT8009, Zelenectide Pevedotin, PEMBROLIZUMAB

    BICYCLE THERAPEUTICS

    Nectin-4 Expressing Advanced Malignancies.

    phase 2 small molecule active

    1 trial

  5. BUL02, Placebo orodispersible tablets, BUL03

    Dr. Falk Pharma GmbH

    Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection

    phase 2 small molecule active

    1 trial

  6. BXCL701 plus Pembrolizumab

    BioXcel Therapeutics

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  7. Balstilimab, CR6086, CR6086

    Alphapharm Pty Ltd

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    phase 2 small molecule active

    1 trial

  8. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial

  9. Baxdrostat, Dapagliflozin Placebo, Forxiga 10 mg film-coated tablets

    AstraZeneca AB

    Chronic kidney disease (CKD) and hypertension.

    phase 2 small molecule active

    1 trial

  10. Befotertinib combined Bevacizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    EGFR

    phase 2 small molecule active

    1 trial

  11. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial

  12. Behavioral Couples Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 2 other completed

    1 trial

  13. Bemarituzumab

    Prime Medicine

    Gastric Cancer

    phase 2 mab completed

    1 trial

  14. Bemarituzumab

    Amgen

    Solid tumours

    phase 2 small molecule active

    1 trial

  15. Bemarituzumab + Flot regimen

    United Therapeutics Europe Ltd

    Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas

    phase 2 small molecule terminated

    1 trial

  16. Bempedoic acid + Ezetimibe FDC Oral Tablet

    Esperion Therapeutics

    Diabetes

    phase 2 small molecule completed

    1 trial

  17. Bendafolin 10 mg/ml Injektionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Xtandi - 40 mg film-coated tablets, Zirabev 25 mg/ml concentrate for solution for infusion, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, 5-Флуороурацил Ебеве 50 mg/ml концентрат за инжекционен и инфузионен разтвор., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Zirabev 25 mg/ml concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  18. Bendatax 6 mg/ ml, TAGRISSO 80 mg film-coated tablets, CISPLATIN, CARBOPLATIN, PEMETREXED, Cisplatin 1mg/ml Concentrate for Solution for Infusion, TAGRISSO 40 mg film-coated tablets, Armisarte 25 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, PACLITAXEL

    AstraZeneca AB

    Unresectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo of belimumab

    Pari Pharma GmbH

    Cryoglobulinemia vasculitis

    phase 2 small molecule active

    1 trial

  20. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  21. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  22. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Colorectal Neoplasms

    phase 2 small molecule terminated

    1 trial

  23. Bevacizumab

    United Therapeutics Europe Ltd

    Recurrent Glioblastoma

    phase 2 mab active

    1 trial

  24. Bevacizumab

    United Therapeutics Europe Ltd

    Colorectal Adenocarcinoma

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources